CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Blood Transfusionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00006182
NCT00006182Phase 3Completed
CompareCT.gov

Stroke Prevention in Sickle Cell Anemia (STOP 2)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Aug 22, 2000·Updated Feb 18, 2016

In Brief

A Phase 3 clinical trial evaluating Blood Transfusion for Blood Disease and 2 related conditions. Completed.

Detailed Summary

To determine how long blood transfusions are needed for primary stroke prevention. Also, to determine the duration of risk associated with abnormal transcranial Doppler ultrasound (TCD) and to determine the specificity of the stroke risk model developed in STOP 1 in patients with abnormal TCD measurements.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Disease, Cerebrovascular Accident, Anemia, Sickle Cell
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 22, 2000
Enrollment StartJul 1, 2000
Study CompletionFeb 1, 2006
TodayJul 2, 2026
Posted 25.9 years ago

Interventions

Blood Transfusionprocedure